United Therapeutics (NASDAQ:UTHR) CEO Sells $5,426,590.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $571.22, for a total transaction of $5,426,590.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $23,141,835.86. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Price Performance

UTHR opened at $570.40 on Friday. The firm has a market cap of $25.00 billion, a P/E ratio of 20.44, a PEG ratio of 1.62 and a beta of 0.60. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $607.89. The company has a 50 day simple moving average of $543.83 and a two-hundred day simple moving average of $497.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the business posted $6.19 earnings per share. Equities analysts anticipate that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on UTHR shares. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Raymond James Financial started coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Bank of America upped their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Finally, HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Ten analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $601.50.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently bought and sold shares of UTHR. Wellington Management Group LLP raised its stake in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. Darwin Global Management Ltd. purchased a new stake in United Therapeutics during the third quarter valued at $317,617,000. Norges Bank purchased a new stake in United Therapeutics during the fourth quarter valued at $293,418,000. Avoro Capital Advisors LLC raised its stake in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after purchasing an additional 341,383 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.